Evidence map›Paper›PMID 27716110›Full record

SynthesisBMC psychiatry2016

Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis.

Varuni Asanka de Silva, Chathurie Suraweera, Suhashini S Ratnatunga, Madhubashinee Dayabandara, Nimali Wanniarachchi, Raveen Hanwella

2 registry-linked trialsOpen access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMC psychiatry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 91 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
91citing papers in PubMed, 13 pooled it
9.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05663749 phase4completedstarted 2022, after this paper: background citation

Efficacy and Safety of Add-on Topiramate vs Metformin on Cardio-Metabolic Profile in Patients With Schizophrenia on Atypical Antipsychotics With Metabolic Syndrome: a Randomized Controlled Trial

Ran2022Enrolled60Registered outcomes5Posted comparisons0ConditionsMetabolic Syndrome, SchizophreniaArmsMetformin, topiramate
PMID 20233913PMID 18082302PMID 31009043PMID 23694688PMID 26781921PMID 21284696PMID 29557263PMID 33454933PMID 3616518PMID 20692814PMID 20207521PMID 19293950other papers from this trial
Open the trial in the graph
NCT07342764 phase4not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Dapagliflozin Versus Metformin for the Management of Antipsychotic-Induced Weight Gain: A Pragmatic Pilot Randomized Controlled Trial

TypeinterventionalSponsorSultan Qaboos UniversityRan2026 to 2028Enrolled110ConditionsAntipsychotic-induced Weight Gain (AIWG), Antipsychotic-induced Weight GainArmsDapagliflozin, Metformin, Common Lifestyle Program
3 · Its place in the literature

Who cites it

91 citing papers in PubMed, 13 syntheses or guidelines pooled it, 219 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Guideline
  6. Pooled it
  7. Pooled it
  8. Guideline
  9. Pooled it
  10. Interventions for the management of obesity in people with bipolar disorder.The Cochrane database of systematic reviews · 2020
    Pooled it
  11. Schizophrenia.Deutsches Arzteblatt international · 2020
    Pooled it
  12. Pooled it
  13. Pooled it
  14. Trial
  15. Trial
  16. Trial
  17. Article
  18. Review
  19. Review
  20. Article

31 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Varuni Asanka de SilvaFaculty of Medicine, University of Colombo, Colombo, Sri Lanka. varunidesilva2@yahoo.co.uk.
Chathurie SuraweeraUniversity Psychiatry Unit, National Hospital of Sri Lanka, Colombo, Sri Lanka.
Suhashini S RatnatungaUniversity Psychiatry Unit, National Hospital of Sri Lanka, Colombo, Sri Lanka.
Madhubashinee DayabandaraFaculty of Medicine, University of Colombo, Colombo, Sri Lanka.
Nimali WanniarachchiUniversity Psychiatry Unit, National Hospital of Sri Lanka, Colombo, Sri Lanka.
Raveen HanwellaFaculty of Medicine, University of Colombo, Colombo, Sri Lanka.
National Hospital of Sri Lanka · LKUniversity of Colombo · LK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMost antipsychotics are associated with weight gain and other metabolic complications. Several randomized trials have shown metformin to be effective, but this still hasn't been included in clinical guidelines on managing antipsychotic induced weight gain.

methodsAll double blind placebo controlled trials assessing the efficacy of metformin in the treatment of antipsychotic induced weight gain were included. Cochrane Central Register of Controlled Trials (CENTRAL) and MEDLINE were searched for the period January 2000-December 2015. Meta-analysis was carried out using the random effects model.

resultsMeta analysis of 12 published studies with a total of 743 patients found that in patients treated with antipsychotics, metformin treatment resulted in significantly better anthropometric and metabolic parameters than placebo. The mean change in weight was -3.27 kg (95 % CI -4.66 to -1.89) (Z = 4.64, p < 0.001). Metformin compared to placebo resulted in significant reduction in BMI [-1.13 kg/m

conclusionThis meta-analysis confirms that metformin is effective in treating antipsychotic induced weight gain in patients with schizophrenia or schizoaffective disorder.

Indexed as

Antipsychotic AgentsDouble-Blind MethodHumansMetforminPsychotic DisordersSchizophreniaWeight GainAntipsychotic AgentsMetformin

Identifiers

PMID27716110
PMCPMC5048618
OpenAlexW2529188573

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.